Stratos Investment Management LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 17.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,756 shares of the medical research company's stock after buying an additional 1,326 shares during the quarter. Stratos Investment Management LLC's holdings in Thermo Fisher Scientific were worth $4,357,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Navalign LLC grew its position in shares of Thermo Fisher Scientific by 2.3% during the first quarter. Navalign LLC now owns 2,142 shares of the medical research company's stock valued at $1,066,000 after purchasing an additional 48 shares in the last quarter. Investment Partners LTD. boosted its position in shares of Thermo Fisher Scientific by 7.0% during the first quarter. Investment Partners LTD. now owns 1,388 shares of the medical research company's stock valued at $690,000 after buying an additional 91 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Thermo Fisher Scientific by 12.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 2,126 shares of the medical research company's stock valued at $1,059,000 after buying an additional 235 shares during the last quarter. Ninety One UK Ltd grew its stake in shares of Thermo Fisher Scientific by 12.2% during the first quarter. Ninety One UK Ltd now owns 569,045 shares of the medical research company's stock valued at $283,157,000 after buying an additional 61,655 shares during the last quarter. Finally, Financial Counselors Inc. grew its stake in shares of Thermo Fisher Scientific by 5.4% during the first quarter. Financial Counselors Inc. now owns 84,545 shares of the medical research company's stock valued at $42,070,000 after buying an additional 4,348 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Scotiabank cut their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Barclays dropped their price objective on Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a research note on Tuesday, June 24th. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $601.05.
Get Our Latest Report on TMO
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock traded down $6.70 on Wednesday, hitting $419.47. 2,735,091 shares of the company were exchanged, compared to its average volume of 1,987,159. The stock has a market capitalization of $158.35 billion, a price-to-earnings ratio of 24.60, a price-to-earnings-growth ratio of 2.27 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average price of $409.11 and a 200 day moving average price of $478.29. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.11 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.33% of the stock is currently owned by insiders.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
